SEC Form SC 13G filed by Candel Therapeutics Inc.

2/9/22 9:11:46 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $CADL alert in real time by email

SC 13G 1 filing.txt SCHEDULE 13G Amendment No. 0 CANDEL THERAPEUTICS INC COMMON STOCK Cusip #137404109 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #137404109 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 0 Item 6: 0 Item 7: 2,262,842 Item 8: 0 Item 9: 2,262,842 Item 11: 7.887% Item 12: HC Cusip #137404109 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 2,262,842 Item 8: 0 Item 9: 2,262,842 Item 11: 7.887% Item 12: IN Cusip #137404109 Item 1: Reporting Person - Select Biotechnology Portfolio Item 2: (a) [ ] (b) [ ] Item 4: Massachusetts Item 5: 2,262,842 Item 6: 0 Item 7: 0 Item 8: 0 Item 9: 2,262,842 Item 11: 7.887% Item 12: IV Item 1(a). Name of Issuer: CANDEL THERAPEUTICS INC Item 1(b). Address of Issuer's Principal Executive Offices: 117 KENDRICK STREET, SUITE 450 NEEDHAM, MA 02494 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 137404109 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 2,262,842 (b) Percent of Class: 7.887% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: 0 (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 2,262,842 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. Not applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 8, 2022 Date /s/ Kevin M. Meagher Signature Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC * IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. Neither FMR LLC nor Abigail P. Johnson has the sole power to vote or direct the voting of the shares owned directly by the various investment companies registered under the Investment Company Act ("Fidelity Funds") advised by Fidelity Management & Research Company LLC ("FMR Co. LLC"), a wholly owned subsidiary of FMR LLC, which power resides with the Fidelity Funds' Boards of Trustees. FMR Co. LLC carries out the voting of the shares under written guidelines established by the Fidelity Funds' Boards of Trustees. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 8, 2022, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of CANDEL THERAPEUTICS INC at December 31, 2021. FMR LLC By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 30, 2018, by and on behalf of Abigail P. Johnson* Select Biotechnology Portfolio By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414.

Get the next $CADL alert in real time by email

Recent Analyst Ratings for

$CADL

Date	Price Target	Rating	Analyst
9/3/2025	$7.00	Buy → Neutral	BofA Securities
6/30/2025	$23.00	Buy	H.C. Wainwright
2/20/2025	$25.00	Buy	Citigroup
2/19/2025	$20.00	Buy	Canaccord Genuity
2/7/2025	$15.00	Buy	BofA Securities
12/2/2022	$11.00	Buy	H.C. Wainwright
11/19/2021	$18.00	Outperform	BMO Capital
8/23/2021	$9.00	Buy	UBS

More analyst ratings

SEC Form SC 13G filed by Candel Therapeutics Inc.

2/9/22 9:11:46 AM ET

$CADL

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $CADL alert in real time by email

Recent Analyst Ratings for

$CADL

Date	Price Target	Rating	Analyst
9/3/2025	$7.00	Buy → Neutral	BofA Securities
6/30/2025	$23.00	Buy	H.C. Wainwright
2/20/2025	$25.00	Buy	Citigroup
2/19/2025	$20.00	Buy	Canaccord Genuity
2/7/2025	$15.00	Buy	BofA Securities
12/2/2022	$11.00	Buy	H.C. Wainwright
11/19/2021	$18.00	Outperform	BMO Capital
8/23/2021	$9.00	Buy	UBS

More analyst ratings

SEC Form SC 13G filed by Candel Therapeutics Inc.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$CADL

SEC Form SC 13G filed by Candel Therapeutics Inc.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$CADL

$CADL
Insider Purchases

Director Manning Paul B bought $7,500,000 worth of shares (1,250,000 units at $6.00) (SEC Form 4)

$CADL
Insider Trading

Chief Medical Officer Nichols William Garrett exercised 937 shares at a strike of $1.29 and sold $6,540 worth of shares (937 units at $6.98) (SEC Form 4)

Chief Medical Officer Nichols William Garrett exercised 781 shares at a strike of $1.29 and sold $3,936 worth of shares (781 units at $5.04) (SEC Form 4)

Director Manning Paul B was granted 1,070,663 shares (SEC Form 4)

$CADL
SEC Filings

Candel Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

SEC Form EFFECT filed by Candel Therapeutics Inc.

Candel Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

$CADL
Analyst Ratings

Candel Therapeutics downgraded by BofA Securities with a new price target

H.C. Wainwright resumed coverage on Candel Therapeutics with a new price target

Citigroup initiated coverage on Candel Therapeutics with a new price target

$CADL
Press Releases

Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board

Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer

Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.

$CADL
Leadership Updates

Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board

Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board

Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer

$CADL
Financials

Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation

Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival

Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights

$CADL
Large Ownership Changes